An observational study in Hyperglycemia, sponsored by University of Colorado, Denver. Enrolling by invitation at 3 sites in United States. Open to participants aged 2 Years to 26 Years. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by University of Colorado, Denver · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 316 studies in Hyperglycemia with a site in United States — 29 open to participants now, 38 under way, 1 of them phase 3. Hyperglycemia · United States.
Among the 316 studies in Hyperglycemia with a site in United States, this one is the 22nd largest by planned enrollment of the 50 observational ones that give a count, is one of 14 that started in 2025, is one of 51 observational ones, reaches primary completion later than 19 of the 37 other live ones, and was the 280th registered.
802 studies on the registry are indexed under Hyperglycemia; 115 are open to participants now.
Browse Hyperglycemia studies →29 of the 316 studies in Hyperglycemia with a site in United States are open now. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 14–26
Indiana University · Sites in United States
Ages 7–25
University of Pittsburgh · Sites in United States
Ages 16–24
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Men only
David K Carroll · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 71 Hyperglycemia studies recruiting now, 42 (59%) set no upper age limit and 23 (32%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 2 Years to 26 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
316 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 30 · Phase 3 27 · Phase 4 43
First in 1998; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is close to the median of 120 across 154 observational studies indexed under Hyperglycemia.
Median enrollment 48 across the 265 interventional studies, 84 across the 50 observational. Of the 258 that completed or were terminated, 111 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 316 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
University of Colorado, Denver has 4 studies filed under Hyperglycemia — fewer than ten, so there is no comparison to draw.
20 of the studies in Hyperglycemia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07215312Eli Lilly and CompanyA Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | 2026-11 |
| NCT07216508Icahn School of Medicine at Mount SinaiLiver Transplant CGM | 2026-11-30 |
| NCT05455619SynDevRx, Inc.Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer | 2026-12 |
| NCT07270016University of PittsburghPilot-Testing Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes | 2026-12 |
| NCT06893341Indiana UniversityMonitoring Exhaled Breath to Noninvasively Detect Glycemic Events | 2026-12-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 316 studies in Hyperglycemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is assessing the feasibility of a continuous glucose monitor during hospital admissions in youth and young adults with hyperglycemia due to diabetes or other underlying conditions that requires frequent glucose monitoring, through patient/family and nursing staff feedback on their perspectives and usability of the system in the hospital will be assessed through surveys. In addition, retrospective glycemic comparisons between CGM data and POC will be conducted.
Youth and young adult patients admitted to the hospital for any reason, but require glucose monitoring during the hospitalization will be enrolled in this study. Participant diagnosis can include type 1 diabetes, type 2 diabetes, medication-induced diabetes, cystic fibrosis-related diabetes, or other causes of hyperglycemia that it has been determined by the hospital team requires frequent glucose monitoring, with or without insulin management.
Enrolled participants will wear a blinded continuous glucose monitor for up to 28 days (2 sensors) or until the end of their hospitalization. In addition, enrolled participants will complete a survey to assess their perspectives on the CGM wear experience and interest in future CGM use during hospitalizations. Nursing staff of the enrolled participant will also be invited to complete a survey regarding their perspectives of CGM use in the hospital setting.
Youth and young adult participants will be admitted to the hospital and have hyperglycemia resulting in an endocrine consult and requiring frequent glucose monitoring.
Nursing staff providing medical care for the youth and young adult participant will be invited to complete a survey on usability of the CGM in the hospital setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Any youth and young adult patient admitted to the hospital and requiring an endocrine consult for frequent glucose monitoring and hyperglycemia management
Device: Freestyle Libre 3 Continuous Glucose Monitor
Nursing staff providing medical care for youth and young adult patients enrolled in the study.
Youth and young adult participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.
Retrospective glycemic CGM and point of care comparison
Glycemic data related to time in range, time hypoglycemic, time hyperglycemic and the time of first onset of hypoglycemia and hyperglycemia will be obtained by both CGM and point of care glucose values.
Time frame: Duration of study, approximately 1 year from study start
Nursing staff perspectives of CGM use in the hospital
Surveys will be provided to the nursing staff associated with an enrolled patient participant to obtain qualitative perspectives on the usability of CGMs in the hospital setting
Time frame: Duration of study, approximately to 1 year from study start
Patient/Family perspectives of CGM use in the hospital
Surveys will be completed by patients/family to evaluate their experience with sensor wear in the hospital, sensor insertion, and goals for glycemic monitoring while in the hospital.
Time frame: Duration of study, approximately 1 year from study start
Feasibility of CGM use through assessment of discontinuation and data loss
Identify the frequency and causes of sensor discontinuation as well as information on sensor data loss.
Time frame: Duration of study, approximately 1 year from study start
Health economics data
Pilot analysis of health economics data from costs related to glycemic monitoring during the hospitalization.
Time frame: Duration of study, approximately 1 year from study start
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Feb 2027, 18 months after the start.
Of 63 non-industry observational studies under Hyperglycemia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's planned 18 months is below that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →